Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial

Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial

Objective To evaluate the clinical efficacy and safety of leflunomide (L) added to the standard-of-care (SOC) treatment in COVID-19 patients hospitalised with moderate/critical clinical symptoms.Design Prospective, open-label, multicentre, stratified, randomised clinical trial.Setting Five hospitals...

Full description

Bibliographic Details
Main Authors: Ling Li, Ines Kralj-Hans, David Fluck, Pankaj Sharma, Siva Mahendran, Zhong Chen, Rita Pereira, Kieran Brack, Sreenivasa Rao Kondapally Seshasai, Jonathan D Belsey, Nandor Marczin, Kuo Li, Adrian Wesek, Alexia Lamorgese, Fatima Omar, Kapila Ranasinghe, Megan McGee, Shiliang Li, Ritesh Aggarwal, Ajay Bulle, Aparna Kodre, Shashank Sharma, Isaac John, Hong Lin Li, Maia Aquino, Vicky Frost, Kirsty Gibson, Maria Croft, Anna Joseph, Maggie Grout, Arun Dewan
Format: Article
Language:English
Published: BMJ Publishing Group 2023-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/4/e068179.full

Internet

https://bmjopen.bmj.com/content/13/4/e068179.full

Similar Items